Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

YOU WONT BELIEVE: Is regeneron pharmaceuticals stock underperforming the s p 500 | Mind Blowing Facts

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Valued at $82.5 billion by market cap, the company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Evkeeza, Libtayo, Inmazeb, Arcalyst, and Zaltrap. 

Companies worth $10 billion or more are generally described as “large-cap stocks,” and REGN perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. REGN has a strong product portfolio, including marketed products such as Eylea and Dupixent. The company's innovative pipeline and successful product commercialization drive its financial performance. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.